资讯

Gut3 天
DNAJ-PKAc fusion heightens PLK1 inhibitor sensitivity in fibrolamellar carcinoma
Background Fibrolamellar carcinoma (FLC), a rare and fatal liver cancer lacking effective drug therapy, is driven by the DNAJ ...
Pharmaceutical Technology on MSN4 天
EditCo Bio secures access to Promega’s technologies in licensing deal
"EditCo Bio secures access to Promega’s technologies in licensing deal" was originally created and published by ...
GEN - Genetic Engineering and Biotechnology News5 天
EditCo, Promega to Combine CRISPR Knock-In Capabilities with Protein-Labeling Tech
The agreement allows EditCo to integrate Promega's HiBiT, HaloTag, and NanoLuc protein tagging tech with its knock-in gene ...
EditCo Bio and Promega Partner to Power a New Era of Biologically Relevant Cell-Based Research
EditCo Bio, Inc. has announced a strategic licensing agreement with Promega Corporation, granting EditCo access to Promega HiBiT, HaloTag®, and NanoLuc® technologies. These advanced protein-tagging ...